BEYFORTUS 50 mg Injectable Solution in Pre-filled Syringe
Ask a doctor about a prescription for BEYFORTUS 50 mg Injectable Solution in Pre-filled Syringe
How to use BEYFORTUS 50 mg Injectable Solution in Pre-filled Syringe
Introduction
Package Leaflet: Information for the User
Beyfortus 50mg solution for injection in pre-filled syringe
Beyfortus 100mg solution for injection in pre-filled syringe
nirsevimab
This medicine is subject to additional monitoring, which will allow for the quick identification of new safety information. You can help by reporting any side effects your child may experience. The last part of section 4 will tell you how to report side effects.
Read all of this leaflet carefully before giving this medicine to your child, because it contains important information for you and your child.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor, pharmacist, or nurse.
- If your child experiences any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. See section 4.
Contents of the pack
- What is Beyfortus and what is it used for
- What you need to know before Beyfortus is given to your child
- How and when to give Beyfortus
- Possible side effects
- Storage of Beyfortus
- Contents of the pack and further information
1. What is Beyfortus and what is it used for
What is Beyfortus
Beyfortus is a medicine given as an injection to protect babies and children under 2 years old against the respiratory syncytial virus(RSV). RSV is a common respiratory virus that usually causes mild symptoms similar to those of the common cold. However, especially in babies, vulnerable children, and older adults, RSV can cause serious diseases, such as bronchiolitis (inflammation of the small airways in the lung) and pneumonia (lung infection) that can lead to hospitalization or even death. The virus is usually more common during winter.
Beyfortus contains the active substance nirsevimab, which is an antibody (a protein designed to bind to a specific target) that binds to the protein that RSV needs to infect the body. By binding to this protein, Beyfortus blocks its action, preventing the virus from entering and infecting human cells.
What Beyfortus is used for
Beyfortus is a medicine used to protect your child against disease caused by RSV.
2. What you need to know before Beyfortus is given to your child
Your child should not use Beyfortus if they are allergic to nirsevimab or any of the other ingredients of this medicine (listed in section 6).
Tell your child's doctor, pharmacist, or nurse if this applies to your child. If you are not sure, consult your child's doctor, pharmacist, or nurse before giving the medicine.
If your child shows signs of a severe allergic reaction,contact the doctor immediately.
Warnings and precautions
Consult your doctor or seek medical help immediately if you notice any signs of allergic reaction, such as:
- difficulty breathing or swallowing
- swelling of the face, lips, tongue, or throat
- severe itching of the skin, with a red rash or raised bumps
Consult your healthcare professional before giving Beyfortus to your child if they have a low number of platelets in the blood (which help blood to clot), a bleeding disorder, or bruise easily, or if they are taking an anticoagulant (a medicine to prevent blood clots).
In certain chronic diseases, where too much protein is lost through the urine or intestine, for example, nephrotic syndrome and chronic liver diseases, the level of protection of Beyfortus may be reduced.
Beyfortus contains 0.1 mg of polysorbate 80 in each 50 mg dose (0.5 ml) and 0.2 mg in each 100 mg dose (1 ml). Polysorbates can cause allergic reactions. Tell your doctor if your child has any known allergy.
Children and adolescents
Do not give this medicine to children between 2 and 18 years of age because it has not been studied in this age group.
Other medicines and Beyfortus
No interactions have been observed between Beyfortus and other medicines. However, tell your doctor, pharmacist, or nurse if your child is taking, has recently taken, or might take any other medicine.
Beyfortus can be given at the same time as vaccines that are part of the national vaccination program.
3. How and when to give Beyfortus
Beyfortus should be given by a healthcare professional as an injection into the muscle. It is usually given in the outer part of the thigh.
The recommended dose is:
- 50 mg for children who weigh less than 5 kg and 100 mg for children who weigh 5 kg or more in their first RSV season.
- 200 mg for children who remain vulnerable to serious RSV disease in their second RSV season (given as 2 injections of 100 mg at separate sites).
Beyfortus should be given before the RSV season. The virus is usually more common during winter (known as the RSV season). If your child is born during winter, Beyfortus should be given after birth.
If your child is going to have heart surgery (cardiac surgery), they may be given an additional dose of Beyfortus after surgery to ensure they have adequate protection for the rest of the RSV season.
If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Side effects may include:
Uncommon(may affect up to 1 in 100 children)
- rash
- injection site reaction (i.e., redness, swelling, and pain where the injection is given)
- fever
Frequency not known(cannot be estimated from the available data)
- allergic reactions
Reporting of side effects
If your child experiences any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Beyfortus
Your doctor, pharmacist, or nurse is responsible for storing this medicine and disposing of any unused product correctly. The following information is for healthcare professionals.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date is the last day of the month shown.
Store in a refrigerator (between 2°C and 8°C). After removal from the refrigerator, Beyfortus should be protected from light and used within 8 hours or discarded.
Store the pre-filled syringe in the outer carton to protect it from light.
Do not freeze, shake, or expose to direct heat.
Disposal of unused medicine and all materials that have come into contact with it should be done according to local regulations.
6. Contents of the pack and further information
What Beyfortus contains
- The active substance is nirsevimab.
- A pre-filled syringe of 0.5 ml solution contains 50 mg of nirsevimab.
- A pre-filled syringe of 1 ml solution contains 100 mg of nirsevimab.
- The other ingredients are: L-histidine, L-histidine hydrochloride, L-arginine hydrochloride, sucrose, polysorbate 80 (E433), and water for injections.
Appearance and pack of Beyfortus
Beyfortus is a colourless to yellowish solution for injection.
Beyfortus is available in:
- 1 or 5 pre-filled syringe(s) without needles.
- 1 pre-filled syringe packed with 2 separate needles of different sizes.
Not all pack sizes may be marketed.
Marketing authorisation holder
Sanofi Winthrop Industrie
82 avenue Raspail
94250 Gentilly
France
Manufacturer
AstraZeneca AB
Gärtunavägen
SE‑152 57 Södertälje
Sweden
You can request more information about this medicine from the local representative of the marketing authorisation holder:
België/Belgique/Belgien Sanofi Belgium Tél/Tel: +32 2 710.54.00 | Lietuva Swixx Biopharma UAB Tel: +370 5 236 91 40 |
| Luxembourg/Luxemburg Sanofi Belgium Tél/Tel: +32 2 710.54.00 |
Ceská republika Sanofi s.r.o. Tel: +420 233 086 111 | Magyarország sanofi-aventis zrt Tel.: +36 1 505 0055 |
Danmark Sanofi A/S Tlf: +45 4516 7000 | Malta Sanofi S.r.l. Tel: +39 02 39394275 |
Deutschland Sanofi-Aventis Deutschland GmbH Tel.: 0800 54 54 010 Tel. from abroad: +49 69 305 21 130 | Nederland Sanofi B.V. Tel: +31 20 245 4000 |
Eesti Swixx Biopharma OÜ Tel: +372 640 10 30 | Norge Sanofi-aventis Norge AS Tlf: + 47 67 10 71 00 |
Ελλ?δα ΒΙΑΝΕΞ Α.Ε. Τηλ: +30.210.8009111 | Österreich Sanofi-Aventis GmbH Tel: +43 1 80 185-0 |
España sanofi-aventis, S.A. Tel: +34 93 485 94 00 | Polska Sanofi Sp. z o. o. Tel.: +48 22 280 00 00 |
France Sanofi Pasteur Europe Tél: 0800 222 555 Appel depuis l’étranger : +33 1 57 63 67 62 | Portugal Sanofi – Produtos Farmacêuticos, Lda. Tel: + 351 21 35 89 400 |
Hrvatska Swixx Biopharma d.o.o. Tel: +385 1 2078 500 | România Sanofi Romania SRL Tel: +40(21) 317 31 36 |
Ireland sanofi-aventis Ireland T/A SANOFI Tel: + 353 (0) 1 4035 600 | Slovenija Swixx Biopharma d.o.o Tel: +386 1 235 51 00 |
Ísland Vistor Sími: +354 535 7000 | Slovenská republika Swixx Biopharma s.r.o. Tel: +421 2 208 33 600 |
Italia Sanofi S.r.l. Tel: 800536389 | Suomi/Finland Sanofi Oy Puh/Tel: +358 (0) 201 200 300 |
Κ?προς C.A. Papaellinas Ltd. Τηλ: +357 22 741741 | Sverige Sanofi AB Tel: +46 8-634 50 00 |
Latvija Swixx Biopharma SIA Tel: +371 6 616 47 50 | United Kingdom (Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0) 800 035 2525 |
Date of last revision of this leaflet:
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
In order to improve the traceability of biological medicinal products, the name and batch number of the administered product should be clearly recorded.
Inspect Beyfortus visually for particles and discoloration before administration. Beyfortus is a transparent to opalescent, colourless to yellowish solution. Do not inject Beyfortus if the liquid is cloudy, discoloured, or contains large or foreign particles.
Do not use it if the Beyfortus pre-filled syringe has been dropped or damaged or if the security seal of the packaging is broken.
Administer the entire contents of the pre-filled syringe as an intramuscular injection, preferably in the anterolateral aspect of the thigh. The gluteal muscle should not be used routinely as an injection site due to the risk of damage to the sciatic nerve.
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a licensed doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to BEYFORTUS 50 mg Injectable Solution in Pre-filled SyringeDosage form: INJECTABLE, 100 mgActive substance: nirsevimabManufacturer: Sanofi Winthrop IndustriePrescription requiredDosage form: INJECTABLE, 150 mg + 150 mgActive substance: tixagevimab and cilgavimabManufacturer: Astrazeneca AbPrescription requiredManufacturer: Astrazeneca AbPrescription required
Online doctors for BEYFORTUS 50 mg Injectable Solution in Pre-filled Syringe
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for BEYFORTUS 50 mg Injectable Solution in Pre-filled Syringe – subject to medical assessment and local rules.
Get updates and exclusive offers
Be the first to know about new services, marketplace updates, and subscriber-only promos.
